Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Make or break for first splice-modulating agents

Nature Reviews Drug Discovery volume 12, pages 813–815 (2013)Cite this article

Subjects

If Duchenne muscular dystrophy drugs that modulate gene splicing can overcome key hurdles, they could boost enthusiasm for related antisense oligonucleotides in other indications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The potential of splice-modulating antisense oligonucleotides.
Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. Make or break for first splice-modulating agents. Nat Rev Drug Discov 12, 813–815 (2013). https://doi.org/10.1038/nrd4151

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4151

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research